Study guide

Acute angle closure, iridotomy and lens extraction

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Acute angle closure, iridotomy and lens extraction

Key Takeaways Explain This Topic AI

Stabilize an acute attack with treatment suited to the mechanism and systemic contraindications.

A patent iridotomy relieves a block component but does not eliminate every cause of angle crowding.

EAGLE supports lens extraction in its eligible population, not every angle-closure suspect.

Last updated: October 2026

Emergency Medical Hypotensive Ladder

Start pressure lowering urgently with contraindications checked. Perform definitive laser when visibility and mechanism permit; do not impose an absolute IOP cutoff as the sole prerequisite.

Step 1: Immediate Systemic & Topical Aqueous Suppression

Systemic Carbonic Anhydrase Inhibitor : Acetazolamide 500 mg IV bolus (or 500 mg orally if the patient is not vomiting), followed by 250 mg orally every 8 hours. Directly decreases aqueous humor secretion by 30% to 40% through inhibition of ciliary epithelial carbonic anhydrase II.

Topical Aqueous Suppressants :

Beta-Blocker : Timolol maleate 0.5% 1 drop.

Alpha-2 Agonist : Brimonidine tartrate 0.2% or Apraclonidine 1% 1 drop.

Topical Carbonic Anhydrase Inhibitor : Dorzolamide 2% 1 drop.

Topical Corticosteroid : Dexamethasone 0.1% or Prednisolone acetate 1% every 15 to 30 minutes for the first 2 hours to suppress intraocular inflammation and prevent permanent PAS adhesion.

Step 2: Systemic Hyperosmotic Agents

Consider hyperosmotic treatment when severe pressure is not adequately controlled, assessing cardiac, renal and hydration risks rather than using one compulsory pressure/time trigger.

Intravenous Mannitol 20% : Administer 1.0 to 2.0 g/kg (approximately 250 to 500 mL of 20% solution) via rapid intravenous infusion over 30 to 45 minutes.

Mechanism : Rapidly elevates serum osmolarity relative to the ocular fluids, creating an osmotic gradient that draws water out of the vitreous body into the intravascular circulation. The resulting reduction in vitreous volume pulls the crystalline lens and iris-lens diaphragm posteriorly, opening the anterior chamber angle.

Precautions : Contraindicated in patients with congestive heart failure (risk of acute pulmonary edema due to sudden intravascular volume expansion), severe renal failure, and dehydration.

Oral Alternative : Glycerol 50% solution (1.0 to 1.5 g/kg orally over crushed ice); caution in diabetic patients (metabolized into glucose, precipitating ketoacidosis).

Step 3: Delayed Topical Miotics (Pilocarpine Protocol)

Caution

Critical Pharmacological Rule Regarding Pilocarpine: When IOP exceeds 30 to 40 mmHg , severe ischemia renders the iris pupillary sphincter muscle completely paralyzed and unresponsive to pharmacological stimulation. Instilling pilocarpine into an eye with IOP > 40 >40 > 40 mmHg is ineffective and hazardous: high concentrations of pilocarpine cause intense ciliary muscle contraction, which increases forward rotation of the ciliary body and produces forward displacement of the crystalline lens, paradoxically worsening anterior chamber crowding.

Correct Protocol : Withhold pilocarpine until IOP has been lowered below 30–40 mmHg using acetazolamide and mannitol. Once sphincter perfusion and responsiveness recover, instill Pilocarpine 1% or 2% (1 drop twice, 15 minutes apart). Pilocarpine stimulates muscarinic receptors, contracting the sphincter muscle to pull the peripheral iris stroma away from the trabecular meshwork.

Contralateral Fellow Eye : Instill Pilocarpine 1% immediately into the unaffected fellow eye to prevent a contralateral acute attack while awaiting bilateral laser iridotomy.

Definitive Procedural Interventions

Once the acute attack is broken, the cornea clears, and anterior chamber inflammation settles, definitive procedural intervention is indicated.

1. Neodymium:YAG Laser Peripheral Iridotomy (Nd:YAG LPI)

Nd:YAG LPI creates a full-thickness optical channel through the peripheral iris, allowing aqueous humor to flow directly from the posterior chamber to the anterior chamber, permanently bypassing pupillary block and flattening the iris contour.

Pre-Treatment : Apraclonidine 1% or Brimonidine 0.2% instilled 30 minutes prior to prevent post-laser IOP spikes; Pilocarpine 1% instilled to stretch the peripheral iris stroma and make it thinner.

Contact Lens : An Abraham or Wise iridotomy lens is applied, which features a high-power convex button (+66 D to +103 D) that magnifies the iris stroma, condenses the laser energy, and dissipates heat at the cornea.

Site selection : Select a suitably thin peripheral iris site with consideration of lid coverage, anatomy and dysphotopsia risk. Superior placement does not eliminate dysphotopsia and is not mandatory in every eye.

Laser settings are selected by iris pigmentation, mechanism, device and response; iridotomy and iridoplasty use different treatment targets.

Confirmation of Patency : Successful full-thickness perforation is confirmed by: 1) a sudden plume of pigment, debris, and aqueous surging from the posterior chamber into the anterior chamber; 2) visible retroillumination through the iridotomy; and 3) direct visualization of the anterior lens capsule through the opening. The diameter should be at least 150 to 200 μ m \mu\text{m} μ m to prevent spontaneous closure from pigment migration.

Post-Laser Management : Measure IOP at 1 hour; prescribe topical prednisolone acetate 1% or dexamethasone 0.1% four times daily for 5 to 7 days.

2. Argon Laser Peripheral Iridoplasty (ALPI)

Argon laser peripheral iridoplasty is indicated when appositional angle closure persists after a patent iridotomy (plateau iris syndrome), or as emergency management when corneal edema prevents a definitive iridotomy during an acute attack.

Laser Parameters : Large spot size ( 200 to 500 μ m \mu\text{m} μ m ), long duration ( 0.5 seconds ), and low power ( 200 to 400 mW ).

Mechanism : Low-energy, slow-burn photocoagulation applied to the extreme iris periphery causes contraction and shrinkage of the underlying stromal collagen, mechanically pulling the peripheral iris roll away from the trabecular meshwork without creating a full-thickness hole.

Clear Lens Extraction: The Landmark EAGLE Trial

Historically, laser peripheral iridotomy was considered the universal first-line intervention for all presentations of primary angle closure. However, the crystalline lens is the primary anatomical driver of crowding in hyperopic eyes.

The Effectiveness in Angle-closure Glaucoma of Lens Extraction (EAGLE) trial, published in The Lancet in 2016, transformed international clinical practice. This randomized controlled trial compared primary clear lens extraction (CLE via phacoemulsification) with standard laser peripheral iridotomy (LPI) in 419 patients aged ≥ 50 \ge 50 ≥ 50 years with newly diagnosed PAC (with IOP ≥ 30 \ge 30 ≥ 30 mmHg) or PACG:

EAGLE outcome: In the selected trial population, clear-lens extraction produced better health-status outcomes and a mean pressure 1.18 mmHg lower at 36 months than standard care. Interpret eligibility and treatment burden; this does not justify extraction for every angle-closure suspect or acute attack.

Quality of Life : Patients treated with clear lens extraction reported significantly higher health-related quality of life, as measured by the European Quality of Life-5 Dimensions (EQ-5D) questionnaire.

Cost-Effectiveness : While upfront procedural costs for phacoemulsification were higher, clear lens extraction was proven to be cost-effective over 3 years due to substantial reductions in long-term medication use, fewer clinical consultations, and avoided filtration surgeries.

Tip

Following the EAGLE trial, European Glaucoma Society guidelines recommend clear lens extraction as an evidence-based primary treatment option for patients aged ≥ 50 \ge 50 ≥ 50 years presenting with Primary Angle Closure with elevated IOP ( ≥ 30 \ge 30 ≥ 30 mmHg) or Primary Angle-Closure Glaucoma.

Mechanism and Safety Before the Ladder

Acute closure requires prompt pressure lowering and definitive mechanism assessment. Check renal function, electrolyte/acid-base disease and contraindications before systemic acetazolamide; assess cardiac and respiratory contraindications before beta-blockers, and cardiac/renal status before hyperosmotics. Pilocarpine is appropriate for selected pupillary-block attacks after pressure reduction, not for aqueous misdirection or forward lens/iris displacement. LPI treats pupillary block but follow-up gonioscopy is required. Persistent closure may involve PAS, plateau iris or lens crowding. Iridotomy location is selected for anatomy and dysphotopsia risk, not compulsory superior placement. EAGLE enrolled adults at least 50 with PAC and IOP at least 30 mmHg or PACG; it excluded acute attacks and advanced disease and should not be extrapolated to every asymptomatic narrow angle.